Print
Hope Without Harm: A New Chapter in Cancer Treatment
In a groundbreaking clinical trial, researchers have achieved what many oncologists once thought impossible: a 100% remission rate in patients with locally advanced rectal cancer—without the use of chemotherapy, radiation, or surgery.
This historic result was published in The New England Journal of Medicine (NEJM) and has sparked global interest in monoclonal antibody therapy as a potential game-changer for treating not only rectal cancer but potentially other hard-to-treat cancers like those of the stomach, pancreas, and bladder.
The Landmark Study That Changed Everything
The study, titled PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer, was led by a team of oncologists at Memorial Sloan Kettering Cancer Center in New York and published in June 2022.
The researchers tested the effectiveness of a monoclonal antibody called dostarlimab, a PD-1 (programmed death-1) immune checkpoint inhibitor, in 12 patients diagnosed with mismatch repair-deficient stage II or III rectal adenocarcinoma.
A Complete Response in Every Patient
Unlike traditional cancer treatments that often result in serious side effects, long recovery times, and potential permanent changes such as colostomies, the patients in this trial were treated solely with dostarlimab.
They received the drug every three weeks for six months. Each patient then underwent at least six months of follow-up monitoring, which included MRI scans, endoscopic evaluation, digital rectal exams, and biopsies to detect residual disease.
The results were nothing short of astonishing: all 12 patients showed a complete clinical response. There were no detectable tumors remaining in any of the patients. Furthermore, none of the patients needed chemotherapy, radiation, or surgery. As of the publication date, no cases of cancer recurrence or progression had been observed, with follow-up periods ranging from six to 25 months.
The NEJM article summarized it this way:
“A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on MRI, FDG-PET, endoscopic evaluation, digital rectal examination, or biopsy.”
– The New England Journal of Medicine, June 2022
The Science Behind Dostarlimab and PD-1 Blockade
So how does dostarlimab work? It belongs to a class of drugs known as immune checkpoint inhibitors. These therapies don’t attack cancer cells directly. Instead, they “unmask” cancer by blocking the PD-1 protein on T cells, which tumors often exploit to avoid immune system detection. By inhibiting this checkpoint, the body’s immune system is reactivated and allowed to recognize and destroy cancer cells.
In patients with mismatch repair-deficient (dMMR) tumors—a genetic mutation found in roughly 5–10% of rectal cancers—this unmasking effect can be especially powerful. dMMR tumors have numerous genetic errors, making them more visible to the immune system once checkpoint inhibition is in place.
This therapeutic approach is part of a broader field called immuno-oncology, which seeks to engage and empower the patient’s own immune system in the fight against cancer.
A Treatment with Minimal Side Effects
Perhaps just as remarkable as the remission rate is the side effect profile of this therapy. According to the study, no grade 3 or higher adverse events were reported. This is in stark contrast to traditional cancer treatments, where side effects often include extreme fatigue, infections, bowel and bladder dysfunction, infertility, and in some cases, permanent colostomies.
Dr. Andrea Cercek, one of the lead authors of the study and an oncologist at Memorial Sloan Kettering, expressed her astonishment in an interview with CNN:
“It’s absolutely incredible. We didn’t expect it. We’ve certainly never seen this before. It’s really what cancer doctors’ dreams are made of—to see a response like this, such incredible efficacy with really almost no toxicity. The patients are feeling great after the treatment, with completely normal body function.”
– CNN Health Interview with Dr. Andrea Cercek
Implications for Other Cancers
While this study focused on a very specific subset of rectal cancer patients—those with dMMR tumors—it opens the door for similar immunotherapy approaches in other cancers that exhibit the same genetic profile.
In fact, the U.S. Food and Drug Administration (FDA) has already approved PD-1 inhibitors like pembrolizumab (Keytruda) and dostarlimab for use in certain cancers with dMMR or microsatellite instability-high (MSI-H) status, including colorectal, endometrial, and gastric cancers.
This trial could lead to a paradigm shift in how we approach cancers traditionally treated with high-toxicity interventions. Trials are now being planned or expanded to test dostarlimab in other dMMR cancers such as those of the bladder, pancreas, and stomach.
A New Era of Targeted, Personalized Cancer Therapy
The success of this small trial underscores the potential of precision medicine, which tailors treatment to a patient’s individual genetic makeup. By identifying genetic markers like dMMR, doctors can more accurately select treatments that are both highly effective and less damaging to the patient’s overall health and quality of life.
Though this particular trial was small—with only 12 participants—the 100% remission rate is almost unheard of in oncology. Larger trials are already underway to confirm the results in broader patient populations. If those results hold, it could mark one of the most important advancements in cancer treatment in recent memory.
Conclusion: From Dream to Reality
While caution is warranted due to the small sample size, the results from this NEJM study are undeniably exciting. They offer a glimpse into a future where cancer treatment doesn’t have to mean suffering and disfigurement, but instead can harness the body’s own immune power for safe and complete healing.
As further research continues, monoclonal antibody therapy may one day become the standard for treating specific cancers—not just a groundbreaking exception.
